Article Versions Notes

Zeuschner P, Hölters S, Stöckle M, Seliger B, Mueller A, Bachmann HS, Grünwald V, Christoph DC, Stenzl A, Grimm M-O, et al. Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study). Cancers. 2021; 13(11):2594. https://doi.org/10.3390/cancers13112594

Zeuschner, Philip, Sebastian Hölters, Michael Stöckle, Barbara Seliger, Anja Mueller, Hagen S. Bachmann, Viktor Grünwald, Daniel C. Christoph, Arnulf Stenzl, Marc-Oliver Grimm, and et al. 2021. "Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)" Cancers 13, no. 11: 2594. https://doi.org/10.3390/cancers13112594

Zeuschner, P., Hölters, S., Stöckle, M., Seliger, B., Mueller, A., Bachmann, H. S., Grünwald, V., Christoph, D. C., Stenzl, A., Grimm, M. -O., Brüning, F., Goebell, P. J., Augustin, M., Roos, F., Harde, J., Benz-Rüd, I., Staehler, M., & Junker, K. (2021). Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study). Cancers, 13(11), 2594. https://doi.org/10.3390/cancers13112594